Saxenda claims on TikTok: separating liraglutide facts from hype

What did @saxendas actually say?

The creator listed what appears to be a series of GLP-1 related drug names, saying: "Sasenda, Loma Forki, Kanhumi, Nia, Rezuntao, In myriatos." That's the entire video. No context, no claims, no explanation of what these words mean or why they matter. Some of these appear to be phonetic approximations of actual medications in this class. Others are unrecognizable as any approved or investigational drug. Without a caption or hashtag context, we're left guessing at the intent.

This kind of content is frustrating to fact-check precisely because it says so little while implying so much. The account name itself, @saxendas, references Saxenda, the brand name for liraglutide, a GLP-1 receptor agonist approved for weight management. That framing sets audience expectations even when the words on screen don't deliver.

Does the science back this up?

There's not enough coherent content here to evaluate against clinical evidence. What we can do is check whether the drug names mentioned correspond to real medications in the GLP-1 class and whether the list is accurate or complete.

"Saxenda" is liraglutide, approved by the FDA for chronic weight management since 2014 (Pi-Sunyer et al., 2015, New England Journal of Medicine). "Retatrutide" or something phonetically close to "Rezuntao" may refer to retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials, which showed up to 24% body weight reduction in a Phase 2 trial (Jastreboff et al., 2023, NEJM). "Mounjaro" or "Kanhumi" could be a garbled version of tirzepatide's brand name. "Nia" and "Loma Forki" do not correspond to any recognized GLP-1 drug, brand name, or INN in clinical use or active trials as of mid-2024.

The list is incomplete and includes terms that don't map to real medications. That's a problem when 65,000 people are watching.

What did they get wrong (or right)?

This one is genuinely hard to score because the content is so thin. If the creator intended to list real GLP-1 medications, they got some right and some badly wrong. Saxenda is real. Something in the vicinity of retatrutide is a real emerging drug. But "Loma Forki," "Kanhumi," and "Nia" don't correspond to anything verifiable in the GLP-1 drug class.

What concerns me more is what's missing. There's no distinction between FDA-approved drugs and those still in trials. There's no mention of the massive safety profile differences between agents in this class. Liraglutide and semaglutide both carry boxed warnings for thyroid C-cell tumors in rodents. Retatrutide is not yet approved for anything. A list that blends approved drugs with trial-phase compounds and apparent fabrications, with zero explanation, is the kind of content that sends people to unregulated sources asking for drugs that either don't exist or aren't available.

What should you actually know?

The GLP-1 class has genuinely changed obesity medicine. That's not hype. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% mean body weight reduction over 72 weeks in adults without diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg producing around 15% weight loss. These are real, peer-reviewed results from large trials.

But the medications in this class are not interchangeable. They have different mechanisms, dosing schedules, side effect profiles, contraindications, and approval statuses. Liraglutide requires daily injection. Semaglutide is weekly. Tirzepatide targets both GLP-1 and GIP receptors. Retatrutide adds a glucagon receptor component and is not approved anywhere yet.

• Never assume a drug mentioned in a TikTok video is FDA-approved or available by prescription.
• Compounded versions of semaglutide are not the same as Ozempic or Wegovy, regardless of what any creator implies.
• If a name doesn't appear on the FDA's drug database, it either doesn't exist or isn't approved for use in the US.
• Side effects across this class include nausea, vomiting, pancreatitis risk, and the rodent thyroid tumor signal that earned the boxed warning.